185 related articles for article (PubMed ID: 22568659)
1. Is there any association between retroperitoneal lymphadenectomy and survival benefit in advanced stage epithelial ovarian carcinoma patients?
Sakai K; Kajiyama H; Umezu T; Shibata K; Mizuno M; Suzuki S; Kawai M; Nagasaka T; Kikkawa F
J Obstet Gynaecol Res; 2012 Jul; 38(7):1018-23. PubMed ID: 22568659
[TBL] [Abstract][Full Text] [Related]
2. What is the role of retroperitoneal exploration in optimally debulked stage IIIC epithelial ovarian cancer? An NRG Oncology/Gynecologic Oncology Group ancillary data study.
Rungruang BJ; Miller A; Krivak TC; Horowitz NS; Rodriguez N; Hamilton CA; Backes FJ; Carson LF; Friedlander M; Mutch DG; Goodheart MJ; Tewari KS; Wenham RM; Bookman MA; Maxwell GL; Richard SD
Cancer; 2017 May; 123(6):985-993. PubMed ID: 27864921
[TBL] [Abstract][Full Text] [Related]
3. The relationship between retroperitoneal lymphadenectomy and survival in advanced ovarian cancer patients.
Fang C; Zhang Y; Zhao L; Chen X; Xia L; Zhang P
BMC Cancer; 2020 Jul; 20(1):654. PubMed ID: 32660444
[TBL] [Abstract][Full Text] [Related]
4. Clinical significance of systematic retroperitoneal lymphadenectomy during interval debulking surgery in advanced ovarian cancer patients.
Iwase H; Takada T; Iitsuka C; Nomura H; Abe A; Taniguchi T; Takizawa K
J Gynecol Oncol; 2015 Oct; 26(4):303-10. PubMed ID: 26197771
[TBL] [Abstract][Full Text] [Related]
5. The prognostic relevance of node metastases in optimally cytoreduced advanced ovarian cancer.
Bachmann C; Brucker SY; Kraemer B; Rothmund R; Staebler A; Fend F; Wallwiener D; Grischke EM
J Cancer Res Clin Oncol; 2015 Aug; 141(8):1475-80. PubMed ID: 25739827
[TBL] [Abstract][Full Text] [Related]
6. Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer: a randomized clinical trial.
Panici PB; Maggioni A; Hacker N; Landoni F; Ackermann S; Campagnutta E; Tamussino K; Winter R; Pellegrino A; Greggi S; Angioli R; Manci N; Scambia G; Dell'Anna T; Fossati R; Floriani I; Rossi RS; Grassi R; Favalli G; Raspagliesi F; Giannarelli D; Martella L; Mangioni C
J Natl Cancer Inst; 2005 Apr; 97(8):560-6. PubMed ID: 15840878
[TBL] [Abstract][Full Text] [Related]
7. Effect of retroperitoneal lymphadenectomy on prognosis of patients with epithelial ovarian cancer.
Wang Z; Xiong Z; Wang S
Chin Med J (Engl); 2003 Apr; 116(4):588-92. PubMed ID: 12875728
[TBL] [Abstract][Full Text] [Related]
8. The impact of systematic retroperitoneal lymphadenectomy on long-term oncologic outcome of women with advanced ovarian clear-cell carcinoma.
Kajiyama H; Suzuki S; Yoshikawa N; Tamauchi S; Shibata K; Kikkawa F
J Gynecol Oncol; 2020 Jul; 31(4):e47. PubMed ID: 32026661
[TBL] [Abstract][Full Text] [Related]
9. Impact of lymphadenectomy on survival after recurrence in patients with advanced ovarian cancer without suspected lymph node metastasis.
Paik ES; Shim M; Choi HJ; Lee YY; Kim TJ; Lee JW; Kim BG; Bae DS; Choi CH
Gynecol Oncol; 2016 Nov; 143(2):252-257. PubMed ID: 27567053
[TBL] [Abstract][Full Text] [Related]
10. Is lymphadenectomy necessary in mucinous ovarian cancer? A single institution experience.
Salgado-Ceballos I; Ríos J; Pérez-Montiel D; Gallardo L; Barquet-Muñoz S; Salcedo-Hernández R; Pérez-Plasencia C; Herrera LA; Cantú de León DF
Int J Surg; 2017 May; 41():1-5. PubMed ID: 28315410
[TBL] [Abstract][Full Text] [Related]
11. Should stage IIIC ovarian cancer be further stratified by intraperitoneal vs. retroperitoneal only disease?: a Gynecologic Oncology Group study.
Rungruang B; Miller A; Richard SD; Hamilton CA; Rodriguez N; Bookman MA; Maxwell GL; Krivak TC; Horowitz NS
Gynecol Oncol; 2012 Jan; 124(1):53-8. PubMed ID: 22032836
[TBL] [Abstract][Full Text] [Related]
12. The effect of lymphadenectomy in advanced ovarian cancer according to residual tumor status: A population-based study.
Zhou J; Zhang WW; Zhang QH; He ZY; Sun JY; Chen QH; Wu SG
Int J Surg; 2018 Apr; 52():11-15. PubMed ID: 29432972
[TBL] [Abstract][Full Text] [Related]
13. Lymphadenectomy in surgical stage I epithelial ovarian cancer.
Svolgaard O; Lidegaard O; Nielsen ML; Nedergaard L; Mosgaard BJ; Lidang M; Mogensen O; Kock K; Blaakaer J; Staehr E; Andersen ES; Grove A; Høgdall C
Acta Obstet Gynecol Scand; 2014 Mar; 93(3):256-60. PubMed ID: 24447203
[TBL] [Abstract][Full Text] [Related]
14. The impact of pelvic retroperitoneal invasion and distant nodal metastases in epithelial ovarian cancer.
Pereira A; Pérez-Medina T; Magrina JF; Magtibay PM; Rodríguez-Tapia A; Pérez-Milán F; Ortiz-Quintana L
Surg Oncol; 2014 Mar; 23(1):40-4. PubMed ID: 24183480
[TBL] [Abstract][Full Text] [Related]
15. Does systematic lymphadenectomy have a benefit on survival of suboptimally debulked patients with stage III ovarian carcinoma? A DEGOG* Study.
Saygili U; Guclu S; Uslu T; Erten O; Ture S; Demir N
J Surg Oncol; 2002 Nov; 81(3):132-7. PubMed ID: 12407725
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic value of selective lymphadenectomy in interval debulking surgery for stage IIIc and IV epithelial ovarian cancer.
Song N; Gao Y
Int J Gynecol Cancer; 2019 May; 29(4):761-767. PubMed ID: 30850437
[TBL] [Abstract][Full Text] [Related]
17. The impact of systematic para-aortic and pelvic lymphadenectomy on survival in patients with optimally debulked ovarian cancer.
Abe A; Furumoto H; Irahara M; Ino H; Kamada M; Naka O; Sasaki M; Kagawa T; Okitsu O; Kushiki N
J Obstet Gynaecol Res; 2010 Oct; 36(5):1023-30. PubMed ID: 21058437
[TBL] [Abstract][Full Text] [Related]
18. Feasibility, safety and clinical outcomes of cardiophrenic lymph node resection in advanced ovarian cancer.
Cowan RA; Tseng J; Murthy V; Srivastava R; Long Roche KC; Zivanovic O; Gardner GJ; Chi DS; Park BJ; Sonoda Y
Gynecol Oncol; 2017 Nov; 147(2):262-266. PubMed ID: 28888540
[TBL] [Abstract][Full Text] [Related]
19. Association of lymphadenectomy and survival in stage I ovarian cancer patients.
Chan JK; Munro EG; Cheung MK; Husain A; Teng NN; Berek JS; Osann K
Obstet Gynecol; 2007 Jan; 109(1):12-9. PubMed ID: 17197582
[TBL] [Abstract][Full Text] [Related]
20. Impact of the number of removed lymph nodes on recurrence-free survival in stage I ovarian clear cell carcinoma.
Takei Y; Takahashi S; Machida S; Taneichi A; Yoshiba T; Takahashi Y; Yoshida C; Saga Y; Matsubara S; Fujiwara H
Int J Clin Oncol; 2018 Oct; 23(5):930-935. PubMed ID: 29679177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
